Erythema Nodosum Disease

Published Date : Nov 2023
Category : Autoimmune Diseases
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

Erythema Nodosum - Dermatologic Disorders

A Complete Overview of Diagnosis and Treatment Market Players

Erythema Nodosum (EN) is a frequent acute nodular septal panniculitis that is primarily limited to the extensor surfaces of the legs and is defined by the abrupt emergence of erythematous, firm, solid, deep nodules or plaques that are painful to palpate. Regardless of the cause, these nodules have a characteristic histological appearance that evolves without necrosis or sequelae and is defined by acute inflammation of the dermo-hypodermic junction and interlobular septa of the hypodermic fat. EN occurs in all ethnicities, sexes, and ages, but is most common in women between the ages of 25 and 40. It is 3–6 times more common in women than in men excluding before puberty when the incidence is the same in both sexes.

EN occurs due to various causes listed below including but not limited to idiopathic, infectious, and a variety of non-infectious cause of erythema nodosum outlined below:

Infections are bacterial, viral, fungal, and parasitic.

Bacterial infections include - Streptococcal infections-most common infectious erythema nodosum etiology commonly streptococcal pharyngitis (28 to 48%), Tuberculosis, Leprosy, Yersinia species (in Europe), Salmonella, Campylobacter gastroenteritis, Mycoplasma pneumonia, Tularaemia, Leptospirosis, Brucellosis, and Lymphogranuloma venereum. Viral infections consist of - infectious mononucleosis, Hepatitis B, Hepatitis C, Human immunodeficiency virus (HIV), Herpes simplex virus (HSV), Epstein-Barr virus (EBV), and Para vaccinia. Fungal infections are Coccidioidomycosis, Histoplasmosis, and Blastomycosis Parasitic infections include Amebiasis and Giardiasis.

Non-infectious causes include drugs, malignancy, lymphoma inflammatory bowel disease, and miscellaneous.

Drugs like antibiotics- Penicillin and Sulphonamides along with miscellaneous drugs are oral contraceptives, bromides, iodides, and TNF-alpha inhibitors. Malignancy includes leukaemia and occult malignancies. Inflammatory Bowel Diseases are Crohn's disease and ulcerative colitis. Miscellaneous includes Sarcoidosis-Lofgren syndrome (a triad of EN, acute arthritis, and hilar lymphadenopathy), pregnancy, Whipple disease, and Bechet disease.

Some pregnant patients develop EN during the second trimester. In addition, recurrence of the disorder also occurs with future pregnancies.

Everyone experiences symptoms of EN differently, and the most common symptoms of Erythema Nodosum include Red, tender bumps on the shins, fever, joint pain, and enlarged lymph nodes in the chest. Young adults are particularly at risk of EN. The erythema nodosum symptoms resemble other skin conditions.

The most prevalent clinical manifestation of acute nodular hypodermis is EN.  Although it is seen at any age, women between the ages of 25 and 40 experience it more frequently. Women are three to six times more affected than males. It is uncommon in the paediatric population to have no sex predominance. Despite their widespread global distribution, there are regional and ethnic variations in the incidences, which are attributed to different triggering etiological variables.

DiseaseLandscape Insights assists the stakeholders by providing data related to the EN marketplace, and knowledgeable choices in healthcare equipment, therapies, and diagnostic techniques where various new technologies and innovations are impacting the disease market and driving higher expansion.

Diagnosis Analysis:

Predominantly a clinical diagnosis of EN is confirmed by laboratory tests and histopathology. The pathology of EN shows inflammation primarily of the septa between the subcutaneous fat lobules without vasculitis. Though, anamnesis (looking for tuberculous contagion, fever, bloody diarrhea, abdominal pain, respiratory problems, dysphagia, etc.) should be conducted as well as a complete clinical examination, always looking for allied signs.

For a positive diagnosis in typical cases, a supplementary examination is not required. It does, nevertheless, have a position in the etiological diagnosis. Considering the clinically oriented investigations must be part of an EN's etiological assessment.

  • Complete blood count with C-reactive protein levels (infectious and inflammatory causes)
  • Chest X-ray (tuberculosis and sarcoidosis)
  • Throat swab and anti-streptomycin O and streptodornase serology (streptococcal infection)
  • Viral serology (preferably two samples at four-week intervals)
  • Stool culture and evaluation for ova and parasites in patients with gastrointestinal symptoms
  • Monteux test or QuantiFERON gold (tests for TB).
  • Deep incisional or excisional skin biopsy.

DiseaseLandscape Insights provides data on current market participants and their products to gain a better knowledge of market dynamics, and it also helps industry leaders with the development of different diagnostic kits and the use of new technologies to improve current diagnostic procedures. DLI services help companies stay competitive, manage the industry's complicated needs, and improve public health by improving EN diagnosis.

Diagnostic Market Players:

Market Players


Roche Diagnostics


Becton, Dickinson, and Company (BD)


Abbott Laboratories


Hologic, Inc.


Edges Medicare Private Limited


Advin Health Care

Biopsy Needle



Iscon Surgical Limited

Biopsy Needle


Biopsy Gun


Cytocore Biopsy Gun

Medtech Devices

Biopsy Gun


Treatment Analysis:

The treatment of Erythema Nodosum holds utmost importance in alleviating the symptoms and improving the quality of life for affected individuals. As companies invest in researching and developing effective treatments for this condition, there is a dual impact on revenue generation. Firstly, pharmaceutical and healthcare companies that successfully bring innovative and effective treatments to the market often experience increased sales and revenue through the commercialization of these products. Secondly, by addressing unmet medical needs and improving patient outcomes, companies enhance their reputation and market standing, fostering trust among healthcare professionals and patients. This positive reputation can, in turn, contribute to sustained revenue growth as the company becomes a trusted player in the healthcare landscape. Therefore, the treatment of Erythema Nodosum not only serves the critical purpose of addressing a medical condition but also presents a strategic opportunity for companies to drive revenue through the development and delivery of impactful healthcare solutions.

For the treatment of Erythema Nodosum extended breaks are preferred. When requested, analgesics are prescribed. In orthostatism, venous compression lessens pain perception. Colchicine (1–2 mg/day), a type of synthetic anti-inflammatory medicine, is recommended until the patient's symptoms diminish. In certain instances, etiologic treatment is crucial, and antibiotic medication is required for treating tuberculosis or streptococcal infections. Sarcoidosis remains in 10% of cases of Lofgren syndrome patients, even though mediastinal adenopathies usually go away in a few months for most patients. For this reason, pulmonary radiography monitoring is advised.

Market participants use DiseaseLandscape Insights' market research and consulting services to investigate and prosper in the EN industry. Through comprehensive research on new goods, technologies, and treatment choices, we help our customers stay competitive and robust. DLI services provide crucial assistance in planning, conducting, and evaluating clinical trials for the development of novel drugs.

Treatment Market Players:

Market Players


Takeda Pharmaceuticals U.S.A., Inc.


Avion Pharmaceuticals'


Hikma Pharmaceuticals USA, Inc.


Sonika Life Sciences Ltd


Dr. Reddy's Laboratories


SiNi Pharma



Clinical Trial Assessment:

The government's growing focus on comparative effectiveness research highlights the significance of clinical trials for evidence-based medicine and healthcare reform. One of the main objectives of health care reform is accomplished with the aid of clinical data, which enables market participants to compare medical therapy correctly.

The table below lists the study names of the ongoing clinical trials along with the stages at which they are being carried out.

Phase 2

Phase 4

A Single Centre, Open-Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients with Erythema Nodosum Leprosum

A Pilot Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum

A Pilot (Double Blind Controlled) Study Randomizing Patients with New Acute ENL to Treatment Either with Ciclosporin or Prednisolone.

Effect of Additional Clofazimine on ENL Reactions in Leprosy

A Pilot Double-Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled with Standard Prednisolone, and Comparing a Group Treated with Ciclosporin to a Group Treated with Additional Steroid Only.




DiseaseLandscape Insights (DLI) helps healthcare enthusiast create and carry out workable plans to stop and control outbreaks of Erythema Nodosum disease. In addition, because of increased awareness and predicted outbreaks, there is a growing demand for clinical evaluations, diagnostic tools, and therapy for Erythema Nodosum diseases.

Our professionals provide vital information and experience to significant players in the production of pharmaceuticals. With the use of DiseaseLandscape Insights, market participants more easily plan and execute clinical trials for novel drugs and therapies, patient recruitment strategies, and regulatory compliance.

DLI also gives business participants a wealth of knowledge about global laws and regulations, industry trends, and rival companies. We help all players in the market establish a more solid foundation in the healthcare industry.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape